NEW YORK (GenomeWeb News) – Epigenomics said today that it has completed the submission of its blood-based test for the detection of colorectal cancer for premarket approval by the US Food and Drug Administration.

The submission of the fourth and final module of its Epi proColon test last month included the results of a comparative, head-to-head study between this test and fecal immunochemical test screening, clinical validation study data, and other clinical study results that were generated during the test's development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.